Increasing Ovary Cancer Cases Drive the Global Ovarian Cancer Drugs Market

Global ovarian cancer drugs market is anticipated to grow at a CAGR of 15.4% during the forecast period (2024–2031). The likelihood of a woman developing ovarian cancer in her lifetime is approximately 1 in 87. The rising incidence of ovarian cancer is a significant factor driving market growth. Furthermore, increasing funding for R&D activities, augmenting demand for personalized treatment and targeted therapies for ovarian cancer, and growing awareness and early detection through advanced technology further accelerate the growth of the ovarian cancer drugs market. 

Browse the full report description of “Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/ovarian-cancer-drugs-market-size

Recent Developments

• In April 2024, the FDA announced full approval of mirvetuximab soravtansine-gynx (Elahere) which marks a significant advancement in treating advanced, platinum-resistant ovarian cancer. Approved based on the MIRASOL trial, it targets tumors overexpressing FR-a protein, improving overall and progression-free survival compared to standard chemotherapy, with fewer serious side effects, heralding a pivotal breakthrough in treatment.

• In April 2024, Merck announced the initiation of a phase II/III study (REJOICE-Ovarian01) for its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in platinum-resistant ovarian cancer. The study, in collaboration with Daiichi Sankyo, follows promising phase I results and will compare R-DXd's efficacy to investigator-chosen chemotherapy.

• In March 2024, the Food and Drug Administration granted full approval to AbbVie and ImmunoGen's cancer drug, mirvetuximab-soravtansine-gynx (Elahere). This drug belongs to a novel class of treatments known for their targeted action on cancer cells.

• In April 2023, AstraZeneca (AZN.L) announced that a late-stage trial showed its cancer drugs Imfinzi and Lynparza, combined with chemotherapy and bevacizumab, met the primary endpoint. The treatment improved progression-free survival in newly diagnosed patients with advanced ovarian cancer lacking specific mutations, aligning with the standard of care.

Market Coverage  

· The market number available for 2023-2031 

· Base year: 2023 

· Forecast period: 2024-2031 

· Segment Covered- 

o By Drug Class

o By Therapy

· Regions Covered- 

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World

• Competitive Landscape: AstraZeneca, F. Hoffmann-La Roche Ltd, Merck Group, Eli Lilly and Co., and Pfizer Inc. among others.

Key questions addressed by the report 

• What is the market's growth rate? 
• Which segment and region dominate the market in the base year? 
• Which segment and region will project the fastest growth in the market? 
• Who is the leader in the market? 
• How are players addressing challenges to sustain growth? 
• Where is the investment opportunity? 

Global Ovarian Cancer Drugs Market Report Segment 

By Drug Class

• Poly Adenosine Diphosphate-ribose Polymerase (PARP) Inhibitors
• Angiogenesis Inhibitors
• PD-L1 Inhibitors

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others (Hormonal Therapy)

Global Ovarian Cancer Drugs Market Report Segment by Region 

North America 

· United States 

· Canada 

Europe 

· UK 

· Germany 

· Italy 

· Spain 

· France 

· Rest of Europe 

Asia-Pacific 

· China 

· India 

· Japan 

· South Korea 

· Rest of Asia-Pacific 

Rest of the World 

· Latin America

· Middle East and Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ovarian-cancer-drugs-market-size